Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus)
Determine Phase 2 dose of study drug
Advanced Cancer|Pancreatic Cancer|Renal Cell Cancer|Non Small Cell Lung Cancer|Colorectal Carcinoma|Endometrial|Uterine
DRUG: Temsirolimus|DRUG: Irinotecan|DRUG: Irinotecan + capecitabine|DRUG: nivolumab
The recommended phase 2 dose (RP2D) of chemotherapy in combination with nivolumab in subjects with advanced cancer., phase 2 dosing of nivolumab + chemotherapy, up to 4 weeks
Frequency of grade 3 or higher treatment-related adverse events by CTCAE 4.03, Identify adverse Events, up to 12 months|Response rate by irRC and response evaluation criteria in solid tumors (RECIST) 1.1 criteria1,2, Identify tumor response, 12 weeks|The overall survival (OS) and progression-free survival (PFS), Assess time until death after treatment, up to 12 months|Quantify changes in amount of blood proteins and circulating tumor DNA in patients enrolled on this study, Assess tumor marker levels, up to 12 months
Determine the recommended phase 2 dose (RP2D) of chemotherapy in combination with nivolumab in subjects with advanced cancer.